

News in brief...

■ **Two steps closer to an effective multi component synthetic HIV vaccine.** Preliminary results from phase I trials of a prototype single-component vaccine showed that human volunteers successfully generated antibodies which could neutralise a primary field HIV-1 isolate, announced United Biomedical Incorporated (UBI[®]) at the annual NIH Conference on Advances in AIDS Vaccine Development. In addition, it was reported that primary field isolates of globally diverse strains of HIV-1 could be neutralised by immunising animals with an experimental multicomponent vaccine. - *Media release*

R0235810